Vincent C. Knick
Research Triangle Park
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Vincent C. Knick.
Investigational New Drugs | 1995
David J. Adams; Vincent C. Knick
SummaryNavelbine® (NVB, vinorelbine tartrate) is a semisyntheticVinca alkaloid in which the catharanthine moiety contains an eight-membered ring in place of the nine-membered ring that is present in all naturally occurring members of the vinblastine group. This modification selectively reduces interaction with anoxalvs mititotic microtubules and may account for the lower neurotoxicity with improved antitumor activity that has been observed in clinical trials with breast, lung and ovarian cancer. We were interested in whether the structural modification in NVB would also alter the drug resistance profile. Specifically, our aim was to determine whether NVB, like vinblastine (VBL), participates in P-glycoprotein (P-gp)-mediated multidrug resistance (MDR). NVB-resistant, murine P388 cells (P388/NVB), were derivedin vivo and used in conjunction with a battery of drug-resistant P388 cell linesin vivo and murine and human tumor cell linesin vitro to develop a resistance profile for NVB. P388/NVB bells were cross-resistant to drugs involved in MDR (doxorubicin, etoposide, amsacrine, vinblastine, vincristine and actinomycin D), but not to the alkylating agents, cyclophosphamide, carmustine, and cisplatin, or to the antimetabolites, 5-fluorouracil and methotrexate. P388/NVB cellular resistance to NVB was stable without drug pressure during continuous passagein vivo for more than ten weeks andin vitro for at least five weeks. These cells exhibited increased expression of P-gp, and a 30-fold level of resistance of NVBin vitro, which was completely reversable with verapamil. The MDR phenotype was confirmed in other tumor models. P388 tumors resistant to vinblastine, vincristine, doxorubicin, and etoposide were cross-resistant to NVBin vivo. Likewise, human KB carcinoma cells resistant to colchicine, MDA-A1R breast carcinoma cells resistant to doxorubicin, and murine B16/F10 melanoma cells transfected with the humanmdr1 gene were cross-resistant to NVBin vitro. Finally, P388 cells resistantin vivo to melphalan, a drug that does not participate in MDR, were cross-resistant to NVB. Therefore, cellular resistance to NVB, like otherVinca alkaloids, may arise by a P-glycoprotein-mediated MDR mechanism, but may also involve non-MDR mechanisms in cells that do not overexpress P-gp.
Cancer Research | 1993
Brian E. Huber; Elizabeth A. Austin; Steven S. Good; Vincent C. Knick; Stephen Tibbels; Cynthia A. Richards
Cancer Research | 1995
Quynh T. Trinh; Elizabeth A. Austin; Doris M. Murray; Vincent C. Knick; Brian E. Huber
Cancer Research | 1993
David S. Duch; Sheila D. Banks; Inderjit K. Dev; Scott Howard Dickerson; Robert Ferone; Louise S. Heath; Joan E. Humphreys; Vincent C. Knick; William Pendergast; Sara Singer; Gary K. Smith; Kathleen A. Waters; H. Robert Wilson
Journal of Medicinal Chemistry | 1990
Kenneth W. Bair; Richard L. Tuttle; Vincent C. Knick; Michael Cory; David D. McKee
Journal of the National Cancer Institute | 1995
Vincent C. Knick; Derek J. Eberwein; Charles Miller
Journal of Medicinal Chemistry | 1991
Kenneth W. Bair; Andrews Cw; Richard L. Tuttle; Vincent C. Knick; Michael Cory; David D. McKee
Cancer Research | 1990
David J. Adams; Pamela J. Watkins; Vincent C. Knick; Richard L. Tuttle; Kenneth W. Bair
Cancer Research | 1983
Richard L. Tuttle; Vincent C. Knick; Carolyn R. Stopford; Gerald Wolberg
Biochemical Pharmacology | 1994
Marilyn Jansen; Michael Dykstra; Jacqueline I. Lee; Jeremy N. Stables; Peter Topley; Vincent C. Knick; Robert J. Mullin; David S. Duch; Gary K. Smith